Unique ID issued by UMIN | UMIN000005687 |
---|---|
Receipt number | R000006721 |
Scientific Title | Liraglutide reduce infarction size in a acute myocardiac infarction patients with Diabetes mellitus |
Date of disclosure of the study information | 2011/06/01 |
Last modified on | 2011/05/31 16:20:48 |
Liraglutide reduce infarction size in a acute myocardiac infarction patients with Diabetes mellitus
LISA Trial
Liraglutide reduce infarction size in a acute myocardiac infarction patients with Diabetes mellitus
LISA Trial
Japan |
Diabetes mellitus
acute myocardiac infarction
Cardiology | Endocrinology and Metabolism |
Others
NO
In acute myocardial infarction patient complicated with diabetes, I examine it against control about an effect on reduction of the myocardial infarction size of Liraglutide
Efficacy
Confirmatory
Pragmatic
Not applicable
Improvement degree of cardiac function expressed in EF(Teichholz method , Simpson method) and EDV at start of therapy, one week later, the time of a discharge, six months later
1. Change of the following item
RBC, WBC, Hb, Ht, Plt, TC, LDL-C, TG, HDL-C, ALT, AST, ganma-GTP, CK, CK-MB, BUN, Cr, BS, HbA1c, 1,5-AG, BNP
2. Coronary angiography (QCA:Quantitative Coronary Analysis) at the time of start of therapy, before a discharge, six months later .
3.Improvement degree of cardiac function expressed by MRI
4.major adverse cardiac events
5.Hypoglycemia event
Interventional
Parallel
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Placebo
NO
NO
Institution is considered as a block.
YES
2
Treatment
Medicine |
Liraglutide
Placebo
20 | years-old | <= |
85 | years-old | >= |
Male and Female
he case that was treated for myocardial infarction to assume the left coronary arteries
Diabetes which have already received a diabetes drugs or the person which became the diagnosis of diabetes during hospitalization
The person who does not receive GLP-1 analog and the DPP-IV inhibitor so far
Case having a serious renal damage and liver damage(Cr>2.0mg/dl, T-Bil>3.0mg/dl, PT<60%, Alb<2.8mg/dl)
CABG enforcement planned case
Case within CABG enforcement three months
Case contraindicated to the dosage of Liraflutide
The case that is using insulin
Case having a serious underlying disease (including a malignant tumor, an infectious disease, DIC)
The case that infarction responsibility blood vessel is a bypass graft
100
1st name | |
Middle name | |
Last name | Koji Sakai |
Shin-Tokyo hospital
Endocrinolory and diabetes internal medicine
473-1 nemoto, matsudo city, Chiba, Japan
+81-47-366-7000
1st name | |
Middle name | |
Last name | koji sakai |
Shin-Tokyo hospital
Endocrinolory and diabetes internal medicine
473-1 nemoto, matsudo city, Chiba, Japan
+81-47-366-7000
kojisakai@sc4.so-net.ne.jp
Shin-Tokyo hospital
none
Self funding
YES
0021-1
Shin-Tokyo hospital
新東京病院
2011 | Year | 06 | Month | 01 | Day |
Unpublished
Preinitiation
2011 | Year | 05 | Month | 06 | Day |
2011 | Year | 06 | Month | 01 | Day |
2014 | Year | 07 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2011 | Year | 05 | Month | 31 | Day |
2011 | Year | 05 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006721
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |